China Merchants International: Chinese Pharmaceutical Stocks Expected to Continue Rising on Innovation Drug Overseas Expansion and Domestic Policy Optimization, Recommends Buying 3SBIO (01530) and Others

Stock News

09/08

China Merchants International released a research report stating that the Chinese pharmaceutical industry is expected to continue its upward trajectory, benefiting from positive factors including innovative drug overseas licensing deals and optimization of domestic centralized procurement policies. The firm recommends buying 3SBIO (01530), GIANT BIOGENE (02367), WUXI XDC (02268), GUSHENGTANG (02273), SINO BIOPHARM (01177), and INNOVENT BIO (01801).

The firm believes that in the short term, valuations of innovative drug companies continue to rise as the market maintains high expectations for the frequency and scale of overseas licensing transactions, though investors should maintain a rational perspective on stock price appreciation opportunities. Looking ahead, the firm expects that the sustained upward momentum for innovative drug companies will primarily stem from overseas partners advancing clinical development of licensed pipelines.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1152030014"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1152030014\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1152030014?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-08 14:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152030014","market":"sh","top_or_hot":-1,"title":"China Merchants International: Chinese Pharmaceutical Stocks Expected to Continue Rising on Innovation Drug Overseas Expansion and Domestic Policy Optimization, Recommends Buying 3SBIO (01530) and Others","media":"Stock News","content":"<p>China Merchants International released a research report stating that the Chinese pharmaceutical industry is expected to continue its upward trajectory, benefiting from positive factors including innovative drug overseas licensing deals and optimization of domestic centralized procurement policies. The firm recommends buying 3SBIO (01530), GIANT BIOGENE (02367), WUXI XDC (02268), GUSHENGTANG (02273), SINO BIOPHARM (01177), and INNOVENT BIO (01801).</p>\n<p>The firm believes that in the short term, valuations of innovative drug companies continue to rise as the market maintains high expectations for the frequency and scale of overseas licensing transactions, though investors should maintain a rational perspective on stock price appreciation opportunities. Looking ahead, the firm expects that the sustained upward momentum for innovative drug companies will primarily stem from overseas partners advancing clinical development of licensed pipelines.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Merchants International: Chinese Pharmaceutical Stocks Expected to Continue Rising on Innovation Drug Overseas Expansion and Domestic Policy Optimization, Recommends Buying 3SBIO (01530) and Others</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Merchants International: Chinese Pharmaceutical Stocks Expected to Continue Rising on Innovation Drug Overseas Expansion and Domestic Policy Optimization, Recommends Buying 3SBIO (01530) and Others\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-09-08 14:36</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>China Merchants International released a research report stating that the Chinese pharmaceutical industry is expected to continue its upward trajectory, benefiting from positive factors including innovative drug overseas licensing deals and optimization of domestic centralized procurement policies. The firm recommends buying 3SBIO (01530), GIANT BIOGENE (02367), WUXI XDC (02268), GUSHENGTANG (02273), SINO BIOPHARM (01177), and INNOVENT BIO (01801).</p>\n<p>The firm believes that in the short term, valuations of innovative drug companies continue to rise as the market maintains high expectations for the frequency and scale of overseas licensing transactions, though investors should maintain a rational perspective on stock price appreciation opportunities. Looking ahead, the firm expects that the sustained upward momentum for innovative drug companies will primarily stem from overseas partners advancing clinical development of licensed pipelines.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信達生物","start_time":0,"source_url":"","article_id":"1152030014","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152030014","pubTimestamp":1757313378,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"China Merchants International released a research report stating that the Chinese pharmaceutical industry is expected to continue its upward trajectory, benefiting from positive factors including...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","600056":"中国医药","01801":"信达生物","BK1589":"北水核心资产","BK1207":"个人用品","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK0188":"融资融券","SG9999004311.SGD":"Nikko AM Shenton Emerging Enterprise Discovery Fund SGD","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","06978":"永泰生物-B","BK0082":"国资改革","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK1141":"生命科学工具和服务","BK0028":"国家队","BK1219":"保健护理服务","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","BK1191":"制药","BK1161":"生物科技","02273":"固生堂","BK1593":"医美概念股","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","BK0175":"白马股","BK0250":"批发","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","BK1515":"抗疫概念","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","BK1574":"生物医药B类股","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","01177":"中国生物制药","02367":"巨子生物","01530":"三生制药","BK0010":"央企","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","BK1583":"高瓴概念","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","BK0185":"二线龙头","02268":"药明合联","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","SG9999014674.SGD":"Nikko AM All China Equity A SGD","BK1521":"挪威政府全球养老基金持仓","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD"},"translate_title":"招商国际：创新药出海及国内政策优化中资医药股有望持续上涨，建议买入三生制药(01530)等","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"600056":1,"01177":1,"01530":1,"01801":1,"02268":1,"02273":1,"02367":1,"06978":1},"content_text":"China Merchants International released a research report stating that the Chinese pharmaceutical industry is expected to continue its upward trajectory, benefiting from positive factors including innovative drug overseas licensing deals and optimization of domestic centralized procurement policies. The firm recommends buying 3SBIO (01530), GIANT BIOGENE (02367), WUXI XDC (02268), GUSHENGTANG (02273), SINO BIOPHARM (01177), and INNOVENT BIO (01801).\nThe firm believes that in the short term, valuations of innovative drug companies continue to rise as the market maintains high expectations for the frequency and scale of overseas licensing transactions, though investors should maintain a rational perspective on stock price appreciation opportunities. Looking ahead, the firm expects that the sustained upward momentum for innovative drug companies will primarily stem from overseas partners advancing clinical development of licensed pipelines.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}